Skip to main
ILMN
ILMN logo

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 7%
Buy 29%
Hold 50%
Sell 7%
Strong Sell 7%

Bulls say

Illumina's clinical consumables revenue demonstrated a mid-single-digit year-over-year increase, indicating ongoing demand and customer acquisition, particularly with the MiSeq i100 Plus appealing to new-to-sequencing customers. The company's strengthened funding outlook from China and the National Institutes of Health (NIH) further supports its positive trajectory in the market. Additionally, Illumina has raised its non-GAAP diluted earnings per share guidance to a range of $4.45 to $4.55, reflecting favorable adjustments and underlying business growth.

Bears say

Illumina's revenue outlook for 3Q25 indicates a projected constant currency decrease of 1.5-2.5% year-over-year, with reported revenue guidance suggesting a decline to between 1.06-1.07 billion. The company anticipates a significant drop in instruments revenue, specifically a decline of 4-6% year-over-year, contrasting with a modest growth in sequencing consumables of only 1-3% excluding China. Additionally, a significant reduction in NovaSeq X shipments compared to both the previous quarter and year-ago levels further underscores concerns regarding Illumina's sales performance and market demand.

Illumina (ILMN) has been analyzed by 14 analysts, with a consensus rating of Hold. 7% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Hold based on their latest research and market trends.

According to 14 analysts, Illumina (ILMN) has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $117.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $117.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.